Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017. Nutlin-3a purchased from Selleck.

    Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NV;SZ2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Lyb2lEPTB;MD62NVI{PyEQvF2= MXHTRW5ITVJ?
H4 Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTwTWM2OD1yLk[2Nlgh|ryP MVnTRW5ITVJ?
PA-1 NWn4fpRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7oc|dUUUN3ME2wMlg4ODl4IN88US=> MX3TRW5ITVJ?
NKM-1 NHnCRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrDSoJsUUN3ME2xMlA1QTNzIN88US=> NVPJNlFjW0GQR1XS
NEC8 MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\6SmpKSzVyPUGuNlE2PzJizszN MWTTRW5ITVJ?
EoL-1-cell NEDTcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL5TWM2OD1zLkK2O|AyKM7:TR?= MUnTRW5ITVJ?
K5 M3rUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFwNEKwO|Ih|ryP M1rOeXNCVkeHUh?=
QIMR-WIL Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwNkC4OVQh|ryP NWO1WWs2W0GQR1XS
MOLT-16 M1HDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPycnYxUUN3ME2xMlc5PjB2IN88US=> M3LQfXNCVkeHUh?=
CHP-212 MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHpd5pKSzVyPUGuPFE{PjlizszN MmTnV2FPT0WU
CTB-1 MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHqTWM2OD1{LkCyNlQ3KM7:TR?= MWDTRW5ITVJ?
MOLT-4 NIezOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnJd|RWUUN3ME2yMlMzQDV|IN88US=> MYDTRW5ITVJ?
A101D M{Xmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLnTWM2OD1{LkO1NFEh|ryP M4HSXXNCVkeHUh?=
DOHH-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojDTWM2OD1{LkSyNlc6KM7:TR?= MljyV2FPT0WU
ES4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml75TWM2OD1{LkSzNVU2KM7:TR?= NWj6WpI4W0GQR1XS
SW780 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz1TWM2OD1{LkWwPFg{KM7:TR?= M2D0[3NCVkeHUh?=
VA-ES-BJ M{XGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj6Z4RiUUN3ME2yMlU1OTFizszN NF7TOXZUSU6JRWK=
RPMI-8866 NVTzRoxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJwNU[yNVQh|ryP NHjlTIxUSU6JRWK=
ML-2 NF\INpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fpU2lEPTB;Mj61OlU4PiEQvF2= NVjhZlJDW0GQR1XS
MSTO-211H NWTOOo0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwNUe0OVEh|ryP MlPqV2FPT0WU
JVM-3 NXrCO3pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIO4fVRKSzVyPUKuOVk{OjRizszN MXrTRW5ITVJ?
A3-KAW M2nxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfvTWM2OD1{Lk[xPFE5KM7:TR?= NF7sTnlUSU6JRWK=
DK-MG M{T6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHLTWM2OD1{Lk[yOFcyKM7:TR?= Ml3DV2FPT0WU
LNCaP-Clone-FGC M3S2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M335e2lEPTB;Mj62OFMyQCEQvF2= M{jiUXNCVkeHUh?=
HT-144 M3[3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHNTWM2OD1{Lk[0OVc4KM7:TR?= M3jRUnNCVkeHUh?=
NB69 NEjDNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJwNkWzN|Qh|ryP NF3JSm9USU6JRWK=
A172 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHLbZhKSzVyPUKuOlc2QDhizszN MWHTRW5ITVJ?
RS4-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHMTWM2OD1{LkeyOFA4KM7:TR?= NIKyVYpUSU6JRWK=
DU-4475 NFHRVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi1Vm1KSzVyPUKuO|k2ODJizszN NVzMNVBRW0GQR1XS
SJSA-1 M33EW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37BPWlEPTB;Mj64NlU2PiEQvF2= M{HNWXNCVkeHUh?=
BV-173 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\6SWdKSzVyPUKuPFQ1OzlizszN MWXTRW5ITVJ?
U-2-OS MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJwOUGwO{DPxE1? Mn7BV2FPT0WU
CHP-134 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjiW4lKSzVyPUKuPVM5QDJizszN NGXiUINUSU6JRWK=
D-502MG M3P2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX32N4lJUUN3ME2yMlk4OTV2IN88US=> NF;CTpJUSU6JRWK=
KS-1 NUDEOotHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWxTWM2OD1|LkCxOlI{KM7:TR?= NXn0bIV5W0GQR1XS
A204 NGnJdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTNwMEW1PFgh|ryP NYrF[mkxW0GQR1XS
KGN NFTsbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nieGlEPTB;Mz6wPFQ6PiEQvF2= NHf3VldUSU6JRWK=
NCI-H292 NH3EO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;XTWM2OD1|LkGyNFI5KM7:TR?= MkLlV2FPT0WU
CAKI-1 NFLUd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvhXIc{UUN3ME2zMlEzPjl2IN88US=> MnnWV2FPT0WU
C2BBe1 NXzDN3JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTNwMUewNlYh|ryP MYDTRW5ITVJ?
NB10 Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi1dXpKSzVyPUOuNlA6PjZizszN MYTTRW5ITVJ?
MHH-NB-11 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnXRnJkUUN3ME2zMlI3QDJ5IN88US=> MWHTRW5ITVJ?
NCI-SNU-1 NH7mTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTNwMke4OFMh|ryP NEDkepBUSU6JRWK=
HCT-116 NILQVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2zR|BKSzVyPUOuN|A{OzVizszN Ml3hV2FPT0WU
G-401 NUXGOYlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLXTWM2OD1|LkO2N|IzKM7:TR?= Ml3TV2FPT0WU
MN-60 NV74WVVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH6RnlKSzVyPUOuOFQxQTJizszN Ml:zV2FPT0WU
SW982 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTNwNUC4OFgh|ryP M1jnc3NCVkeHUh?=
RKO NWXvcHB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTNwNUO5N|Yh|ryP NF7uWmVUSU6JRWK=
D-283MED NWDLPJJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH3O2lKSzVyPUOuOVc6QDZizszN NWTnWXh6W0GQR1XS
LB996-RCC NXHlSIJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fjVmlEPTB;Mz62NlU2QCEQvF2= M{W2OnNCVkeHUh?=
A549 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrsPIJzUUN3ME2zMlY{PTV{IN88US=> NVrhOVRmW0GQR1XS
LB2241-RCC NYLpUWJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LwRmlEPTB;Mz62OVcxQCEQvF2= M13wOXNCVkeHUh?=
SK-HEP-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTNwN{SyPVch|ryP NVjrTpZKW0GQR1XS
G-402 M2HLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVznNXl6UUN3ME2zMlgxQDN{IN88US=> NEfK[plUSU6JRWK=
GOTO NGPOZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTNwOESzN|Mh|ryP MlvpV2FPT0WU
LOXIMVI M3PK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX2Z|VKSzVyPUOuPFU3PzVizszN NV3ico9EW0GQR1XS
NH-12 M2O3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf6TWM2OD12LkCxPVU6KM7:TR?= NHjnOYFUSU6JRWK=
CTV-1 NFvWTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTRwMEe5O|Mh|ryP MYLTRW5ITVJ?
CP50-MEL-B NXzlUok3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f4c2lEPTB;ND6yOFM6OiEQvF2= NID3XY1USU6JRWK=
RH-18 M4rMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:1WlZKSzVyPUSuNlc4ODZizszN NH;RR|hUSU6JRWK=
NB17 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULifZptUUN3ME20MlMyPzZ6IN88US=> NVTUXm9lW0GQR1XS
A375 MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzWd|NKSzVyPUSuN|M2OjRizszN MXTTRW5ITVJ?
IST-MES1 NYnZZ5JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfyeJNKSzVyPUSuOFE1OTFizszN NGO5U5lUSU6JRWK=
MZ2-MEL MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW0VZV3UUN3ME20MlUxOTV3IN88US=> NFrXeHBUSU6JRWK=
CAL-54 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M165W2lEPTB;ND61N|AyQSEQvF2= NW\JdGpTW0GQR1XS
NCI-H28 NYixXIRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS3XWJxUUN3ME20MlYzPzF5IN88US=> NYLIR2xzW0GQR1XS
D-247MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvTSJY2UUN3ME20Mlc2ODd{IN88US=> NWq3[XluW0GQR1XS
NCI-H460 NWDDOGg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i0dGlEPTB;ND65NVEzPyEQvF2= Mke2V2FPT0WU
MCF7 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnLUYh{UUN3ME21MlQ1OjR2IN88US=> NIjDbIZUSU6JRWK=
697 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTVwNES1OUDPxE1? Mki5V2FPT0WU
ONS-76 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTVwNUewNFkh|ryP NYPHboZWW0GQR1XS
C32 M4D4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrxTWM2OD13Lk[wNFI6KM7:TR?= NGDic4dUSU6JRWK=
OS-RC-2 M1;EUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTVwN{O4PFch|ryP Ml\RV2FPT0WU
MEL-HO MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6zTWM2OD13Lki1OlY4KM7:TR?= MkWxV2FPT0WU
LoVo MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTZwMEG2NlQh|ryP NFzPV3JUSU6JRWK=
AGS NV2zZVhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrpdIl1UUN3ME22MlE1QDJ6IN88US=> Ml[wV2FPT0WU
GI-ME-N MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTZwMkK0NlEh|ryP MVPTRW5ITVJ?
H-EMC-SS NGrRZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLNTWM2OD14LkO4OkDPxE1? NVzkO2JGW0GQR1XS
RVH-421 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLETWM2OD14LkSyOFI5KM7:TR?= NUXwV21YW0GQR1XS
SW954 NGXjbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnUe4JKSzVyPU[uOVU2PzJizszN M3nvNnNCVkeHUh?=
NB5 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\0TWM2OD14LkW2NVg{KM7:TR?= NYXpd4xCW0GQR1XS
NCI-H2122 NGHjT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DSU2lEPTB;Nj61PFc6OyEQvF2= M{DERXNCVkeHUh?=
AM-38 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTZwN{W2N|kh|ryP NWG1[5R6W0GQR1XS
KNS-81-FD MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTZwN{[0PVQh|ryP NYW2W2pMW0GQR1XS
LS-513 NV;JVmE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PFT2lEPTB;Nj63PVAzPiEQvF2= Mm\MV2FPT0WU
A427 NFm5N3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlKwTWM2OD14Lki3PFI6KM7:TR?= NFjoNlRUSU6JRWK=
WM-115 NVj1VWZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfYTWM2OD14LkmzNlMh|ryP MW\TRW5ITVJ?
COLO-829 NYfyO|hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTdwMkSxPFgh|ryP NYLFWXBOW0GQR1XS
NCI-H1650 NHrJXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjQTWM2OD15LkO5NlI5KM7:TR?= M37LO3NCVkeHUh?=
NCI-H358 NHrocHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTLS25KUUN3ME23MlQ1QDd7IN88US=> MYfTRW5ITVJ?
HT-1080 NEThNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLlTWM2OD15LkS4NlU1KM7:TR?= MX7TRW5ITVJ?
HCC2218 M33CXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTdwNkK5O{DPxE1? MUDTRW5ITVJ?
NCI-H661 M1HaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\4bJdKSzVyPUeuPFcxPjlizszN NH7vfYFUSU6JRWK=
KM-H2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP0TWM2OD15Lki4Olk1KM7:TR?= MXTTRW5ITVJ?
RPMI-2650 MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnmNGJEUUN3ME23Mlk1PDF2IN88US=> MVnTRW5ITVJ?
NCI-H226 NFP4WoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrDc3lbUUN3ME24MlIyOTJ{IN88US=> M4rjNHNCVkeHUh?=
MKN45 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LQSGlEPTB;OD6yOlYxOiEQvF2= NF;LdJBUSU6JRWK=
D-392MG MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL4flhKSzVyPUiuOVI4OjJizszN NFvVVmJUSU6JRWK=
RCC10RGB MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjHb4o2UUN3ME24Mlg3Pjl3IN88US=> MlPyV2FPT0WU
CAL-51 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLhU3RGUUN3ME25MlExOjVzIN88US=> M4DyOnNCVkeHUh?=
COLO-678 M3\ieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTlwM{K4NVEh|ryP M4rFfXNCVkeHUh?=
SK-MEL-24 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELycYJKSzVyPUmuOVU5PTZizszN Mn7tV2FPT0WU
SK-MEL-30 Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXjSG9KSzVyPUmuPVQ1PzZizszN MmnMV2FPT0WU
MMAC-SF NVTnXGNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFyLkO5OlEh|ryP M{TmNHNCVkeHUh?=
NTERA-S-cl-D1 MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjsU3dKSzVyPUGwMlY2ODhizszN NGTuOYhUSU6JRWK=
NB12 NEDR[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe3Om9JUUN3ME2xNU42ODNizszN MnLwV2FPT0WU
UACC-257 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHTe5JKSzVyPUGxMlg3QTVizszN MonzV2FPT0WU
LAN-6 NXHWbFRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS0Z3FKSzVyPUGxMlk6OjhizszN MYnTRW5ITVJ?
SW1573 NXP3R5V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTMVlJKSzVyPUGyMlMxQDZizszN M1vnNHNCVkeHUh?=
NMC-G1 NF3YWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT2bIRYUUN3ME2xNk41OTd3IN88US=> NX7qV4tlW0GQR1XS
SHP-77 NX\pXnF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmycGlvUUN3ME2xNk42PTd2IN88US=> NV;SbWlpW0GQR1XS
IGROV-1 NV\UcJpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF{Lk[1O|Mh|ryP M{OyRXNCVkeHUh?=
22RV1 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPsTWM2OD1zMj64NFU6KM7:TR?= MYXTRW5ITVJ?
SK-MEL-3 MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDKU4h[UUN3ME2xN{4{QTd|IN88US=> NHv6SJNUSU6JRWK=
NCI-H1563 NVrTPYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvCTWM2OD1zMz60NlAzKM7:TR?= NUfme|M6W0GQR1XS
IGR-1 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF2LkCzOFch|ryP M4fJbXNCVkeHUh?=
EW-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\BWGVtUUN3ME2xOE4yPjN7IN88US=> Mlz1V2FPT0WU
JEG-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF2LkS5OVMh|ryP MlOxV2FPT0WU
ES3 NEnGZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[zTWM2OD1zND62OVYzKM7:TR?= MVzTRW5ITVJ?
MDA-MB-175-VII M4[0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV72[phpUUN3ME2xOE44OTFzIN88US=> M1TlSnNCVkeHUh?=
P30-OHK MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml23TWM2OD1zNT6wOFk3KM7:TR?= NFnpZ3NUSU6JRWK=
GP5d MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfETWM2OD1zNT6xOFY3KM7:TR?= NEjoRZVUSU6JRWK=
HMV-II Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S3c2lEPTB;MUWuN|M{OyEQvF2= NXTjNHllW0GQR1XS
COLO-679 M4nKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPnUZZKSzVyPUG1MlUxOSEQvF2= NHfzXFJUSU6JRWK=
JAR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXziZ4N1UUN3ME2xOU44OjB3IN88US=> M{X0cHNCVkeHUh?=
NCI-H1666 NFTGSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnwUo1KSzVyPUG1Mlk{QTlizszN MmDnV2FPT0WU
SW48 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPu[YJKSzVyPUG1Mlk2OTZizszN NUHRXIFlW0GQR1XS
NCI-H720 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTKe5FKSzVyPUG1Mlk6QDlizszN M4rtbHNCVkeHUh?=
HT-1197 NXvROHV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF4LkCzOVIh|ryP NWH4UpdrW0GQR1XS
HL-60 MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF4LkCzPFQh|ryP MWDTRW5ITVJ?
BEN NFLMWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jyZ2lEPTB;MU[uOVY{QCEQvF2= MUHTRW5ITVJ?
HAL-01 NFLS[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\iPWlEPTB;MU[uPFkxQSEQvF2= NXyxepRQW0GQR1XS
SW900 M{iySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofQTWM2OD1zNj65NVMzKM7:TR?= NYr4[|VWW0GQR1XS
SBC-1 NXy3SpdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvwTWM2OD1zNz61OFI6KM7:TR?= MkLvV2FPT0WU
SH-4 NUj2VYhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF5LkW4OFEh|ryP M2L5PHNCVkeHUh?=
UACC-62 NYnXPFVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF5Lke2N|ch|ryP M3KxbnNCVkeHUh?=
BHT-101 NWWzc3V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6xRVBkUUN3ME2xPU45PzB3IN88US=> NV3HU3ZYW0GQR1XS
DB NX:xfYdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJzLkW2OFkh|ryP M{\5PXNCVkeHUh?=
SK-MEL-1 NFLLS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfwZlhKSzVyPUKxMlU5PzJizszN MoXNV2FPT0WU
NCI-H747 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrMb3h5UUN3ME2yNk44Ozd7IN88US=> NUK5Oo1OW0GQR1XS
SK-LU-1 M{jJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ|LkO1NlQh|ryP M3;GZ3NCVkeHUh?=
KG-1 MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HEbWlEPTB;MkOuOFk1PiEQvF2= MVzTRW5ITVJ?
LXF-289 NFj4Z5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jOT2lEPTB;MkOuO|E1KM7:TR?= M3u4e3NCVkeHUh?=
HCC1954 M{HwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzuTWM2OD1{ND64PFQ1KM7:TR?= NFHTR2dUSU6JRWK=
Ramos-2G6-4C10 NXHqXoo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHnTWM2OD1{Nj60PVgyKM7:TR?= NHHjWYZUSU6JRWK=
DBTRG-05MG M2TrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Ll[GlEPTB;Mk[uOlQ5QCEQvF2= MnjxV2FPT0WU
NCI-H2052 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofoTWM2OD1{Nz61Olg1KM7:TR?= NF3id3ZUSU6JRWK=
RMG-I MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K2emlEPTB;MkmuOFE{QSEQvF2= NUjkVI5DW0GQR1XS
H9 M1LGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojXTWM2OD1|MT6zNFA5KM7:TR?= MV7TRW5ITVJ?
GR-ST NHP0eW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTN{LkS0OVMh|ryP MX;TRW5ITVJ?
Mo-T Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXHTWM2OD1|Mj61NFQ3KM7:TR?= M1TSOHNCVkeHUh?=
SW1088 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET6cXdKSzVyPUOyMlk5ODFizszN NYDuPHJoW0GQR1XS
LB2518-MEL MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzNZZJKSzVyPUOzMlA4QTdizszN MUfTRW5ITVJ?
NCI-H82 M1GxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN|LkG2OlEh|ryP MmPwV2FPT0WU
LAMA-84 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu4TWM2OD1|ND62NFc{KM7:TR?= M{fzSnNCVkeHUh?=
KYSE-450 NIjYUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\rdlJKSzVyPUO0MlY4PzZizszN MUXTRW5ITVJ?
LU-99A M2XCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L1OGlEPTB;M{WuNFAxPyEQvF2= MVrTRW5ITVJ?
BE-13 NHrHbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTN3Lk[1OFUh|ryP NX[2[FNnW0GQR1XS
GAK MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vH[WlEPTB;M{WuOlk2KM7:TR?= NX3qZYo2W0GQR1XS
NCI-H1573 M4rJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTmTWM2OD1|NT64PFE5KM7:TR?= MUDTRW5ITVJ?
AsPC-1 Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj0bm5pUUN3ME2zOk4yPTJ5IN88US=> MlLYV2FPT0WU
HDLM-2 NW\5S2w2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN4LkOxOkDPxE1? MVLTRW5ITVJ?
NCI-H441 NVnCdndWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULre4pUUUN3ME2zO{4xPjlzIN88US=> MWXTRW5ITVJ?
CAL-27 NVK1XmtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j6XGlEPTB;M{euO|I{OSEQvF2= MVjTRW5ITVJ?
OVCAR-3 NIj2coZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTN7LkOxPFEh|ryP M2HJVHNCVkeHUh?=
RPMI-8226 M4S0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\PVnZKSzVyPUO5MlU6QCEQvF2= NIS1VlVUSU6JRWK=
EFO-21 MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTRyLkW4NVQh|ryP NGXXXnJUSU6JRWK=
SNU-C2B NX3MWXl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFry[XdKSzVyPUSxMlUxQDRizszN MojTV2FPT0WU
VM-CUB-1 M4H3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXndIpKSzVyPUSzMlgxOzdizszN NWS5cHZjW0GQR1XS
NCI-H2087 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PSOGlEPTB;NEWuNFI{OyEQvF2= Mo\OV2FPT0WU
EW-16 NEXqb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULtfJpzUUN3ME20Ok4{OTN5IN88US=> NU\UfFVsW0GQR1XS
SK-N-AS MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLITWM2OD12Nj63NVY4KM7:TR?= M3;tbnNCVkeHUh?=
COR-L105 NGLjV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PRcGlEPTB;NE[uPFg2PyEQvF2= MkW1V2FPT0WU
DEL NGrse41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX2TWM2OD12OD6wOFI6KM7:TR?= NFT6R|RUSU6JRWK=
JVM-2 MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTR6LkC1OVgh|ryP MXjTRW5ITVJ?
KARPAS-45 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\weoFvUUN3ME20PU41PTN6IN88US=> M3viSnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID